Quick Answer
Aprea Therapeutics, Inc. reported Operating Income of -$13.23 million for fiscal year 2025.
Aprea Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$13.23M | +7.6% |
| 2024 | -$14.32M | +7.4% |
| 2023 | -$15.47M | +86.4% |
| 2022 | -$113.39M | -202.8% |
| 2021 | -$37.45M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.12M | +23.9% | +8.0% |
| June 30, 2025 | -$3.39M | +11.9% | +17.1% |
| March 31, 2025 | -$4.09M | -29.7% | +0.3% |
| September 30, 2024 | -$4.10M | -16.3% | -6.5% |
| June 30, 2024 | -$3.85M | -5.3% | -22.1% |
| March 31, 2024 | -$3.15M | +31.9% | +10.6% |
| September 30, 2023 | -$3.52M | +16.1% | +3.5% |
| June 30, 2023 | -$3.65M | +96.3% | +21.0% |
- Aprea Therapeutics, Inc. showed an increase of +7.6% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, Aprea Therapeutics, Inc.’s operating income has grown by 64.7% (from -$37.45 million to -$13.23 million).
- The most recent figure is from Aprea Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: